PwPepwise

GHRP-2

Growth Hormone

a.k.a. Pralmorelin

Ghrelin receptor agonist

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic peptide that stimulates the pituitary gland to release growth hormone (GH).

§Dosing at a glance

4 protocols · from the research
What it's forDoseHow oftenHowFor how long
into a vein (IV) Infusion — Critical Illness / Neuroendocrine Research1 mcg/kg——5 days
IV Bolus — Acute Stimulation Testing1 mcg/kg———
Continuous 24-Hour IV Infusion — Research Protocols in Healthy Adults1 mcg/kg———
into the nose Administration50–200 mcgTwice dailyIntranasalSprayed into the nose.48 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

GHRP-2 (Growth Hormone-Releasing Peptide-2) is a synthetic peptide that stimulates the pituitary gland to release growth hormone (GH). It works by activating specific receptors in the brain and pituitary that amplify the body's natural GH pulses, making it a powerful tool for studying and potentially restoring GH secretion in various conditions.

In clinical research, GHRP-2 has demonstrated robust GH-stimulating effects across a wide range of populations, including healthy adults, postmenopausal women, and critically ill patients. In studies of prolonged critical illness, continuous GHRP-2 infusion produces 4- to 10-fold increases in pulsatile GH secretion and meaningfully raises IGF-1 levels within 24 hours5, while also appearing to reduce protein breakdown and support anabolic recovery3. When combined with other hormonal therapies, GHRP-2 may help restore coordinated function across multiple hormonal axes simultaneously11. Research also shows that the effectiveness of GHRP-2 is influenced by factors such as sex hormone levels, age, and body fat, with estrogen and testosterone both playing modulatory roles1,9,13. Its effects on growth promotion in GH-deficient children via intranasal delivery appear limited20, highlighting that route of administration and underlying condition are important determinants of clinical outcome.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

GHRP-2 (pralmorelin; His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the canonical receptor for the endogenous orexigenic peptide ghrelin. By activating GHS-R1a at both the hypothalamic and pituitary levels, GHRP-2 amplifies GH release through mechanisms that are partially independent of, yet synergistic with, the canonical GHRH/somatostatin regulatory axis. At the pituitary somatotroph, GHS-R1a coupling to Gq/11 proteins elevates intracellular calcium via phospholipase C activation, directly triggering GH exocytosis. At the hypothalamic level, GHRP-2 is thought to suppress somatostatinergic tone and potentiate GHRH neuronal activity, collectively amplifying the amplitude of GH secretory bursts without altering pulse frequency10.

The functional distinction between GHRP-2 and GHRH pathways is demonstrated by their differential sensitivity to physiological modulators. Abdominal visceral fat is the dominant negative determinant of GHRH efficacy (R²=0.41), while IGF-1 is the primary positive determinant of GHRP-2 efficacy (R²=0.31)17, suggesting GHRP-2 acts through a feedback-regulated GHS-R pathway that is more independent of adiposity-driven somatostatin tone. GHRP-2 efficacy is also notably preserved during experimentally induced short-term hypogonadism — unlike GHRH-driven responses — and is independent of abdominal visceral fat, IGF-1, and IGFBP concentrations under those conditions16.

Sex steroids are important modulators of GHRP-2 signaling. Estradiol selectively potentiates the GHRP-2 pathway: it enhances GHRP-2-stimulated incremental peak GH release by 1.58-fold under basal conditions and rescues GHRP-2-stimulated GH from autofeedback suppression (1.7-fold enhancement under GH autoinhibition), without significantly affecting GHRH-stimulated GH output9. This selectivity suggests estradiol specifically sensitizes the GHS-R/effector pathway rather than acting through a generalized somatotropic mechanism. Testosterone independently and positively predicts GHRP-2-stimulated pulsatile GH secretion1, with estradiol derived via aromatization likely mediating part of this effect in men14. Peripheral ERα-dependent mechanisms modulate the waveform (duration and shape) of GH secretory bursts, while GHRP-2 lengthens GH secretory burst duration independently of estradiol status18.

Beyond the GH axis, GHRP-2 exerts broader neuroendocrine effects. It stimulates cortisol secretion through presumed activation of the hypothalamic-pituitary-adrenal axis via GHS-R1a expressed in corticotroph-regulating neurons15, and modestly elevates prolactin10. Uniquely, GHRP-2 — but not GHRH or TRH — synchronizes the pulsatile nocturnal secretion of GH, TSH, and prolactin simultaneously in critically ill patients11, implying a role for a broader endogenous GHRP-like ligand in coordinating anterior pituitary rhythmicity. When administered to critically ill patients with protracted illness, GHRP-2 infusion reactivates the somatotropic axis with preserved pulsatility and appropriate feedback inhibition, normalizing IGF-1, IGFBP-3, and acid-labile subunit levels within 24–48 hours3,4,5, demonstrating that somatotroph responsiveness remains intact even in severely catabolic states.

§04Evidence & efficacy

Evidence base
223Studies
119Human
76Animal

GHRP-2 robustly stimulates pulsatile GH secretion across multiple populations and administration contexts. In critically ill patients with blunted spontaneous GH pulsatility, continuous IV infusion at 1 mcg/kg/hour produces 4- to 6-fold increases in mean GH concentration and GH secretory burst amplitude, with a 61% rise in serum IGF-1 within 24 hours5. Combined administration with GHRH further amplifies these effects, exceeding 10-fold GH amplification and producing 106% IGF-1 increases within 45 hours4. These synergistic effects on the GH/IGF-1 axis have been replicated across multiple independent RCTs in critical illness3,4,5,6,7,8.

In healthy postmenopausal women, 24-hour continuous GHRP-2 infusion produces a 7.7-fold increase in mean serum GH and approximately 102 mcg/L rise in IGF-110, with the GH response further amplified approximately 8.8-fold when combined with oral estradiol12.

In the context of prolonged critical illness, five-day infusion of GHRP-2 combined with TRH increases osteocalcin by 19%, raises leptin by 32%, and reduces the urea/creatinine ratio, indicating reduced protein catabolism3. Triple-combination therapy (GHRP-2 + TRH + GnRH) additionally increases testosterone by up to 312% and further reduces ureagenesis6.

GHRP-2 also uniquely synchronizes the pulsatile release of GH, TSH, and prolactin in critically ill patients — an effect not achieved by GHRH or TRH alone11, suggesting a broader neuroendocrine coordinating role.

The effectiveness of GHRP-2 is modulated by sex steroids, age, and adiposity. Testosterone positively predicts GHRP-2-stimulated GH responses1, estradiol selectively rescues GHRP-2-stimulated GH from autofeedback suppression9, and BMI negatively predicts pulsatile GH responses during GHRP-2 infusion14. Age independently attenuates GH responses to GHRP-2, with postmenopausal women showing approximately 29–38% of premenopausal GH burst responses19.

Intranasal GHRP-2 in GH-deficient children, while stimulating endogenous GH secretion, did not produce significant improvements in height SD score or IGF-1 levels over 48 weeks20, indicating that transient GH pulses via this route are insufficient for growth promotion in this population.

§05Safety

Across multiple RCTs involving both healthy volunteers and critically ill patients, GHRP-2 administered via IV infusion has demonstrated a generally acceptable tolerability profile. No serious adverse events were reported in studies using continuous infusion protocols at 1 mcg/kg/hour for periods ranging from 21 hours to 5 days3,4,5,6,8.

The most consistently observed off-target endocrine effects include modest elevations in cortisol and prolactin. In a 24-hour infusion study in healthy postmenopausal women, GHRP-2 produced approximately a 32% increase in serum cortisol and a 76% increase in prolactin, while having no significant effects on LH, FSH, or TSH10. GHRP-2 also stimulates cortisol secretion acutely, with peak cortisol approximately 47% above baseline saline conditions, an effect that increases with advancing age15. In critically ill patients, cortisol levels were not significantly altered by GHRP-2 infusion despite pre-existing elevations, suggesting no meaningful HPA axis overstimulation in that context5.

An important signal identified in the critical illness literature is that GHRP-2 alone, and GHRP-2 combined with TRH, were associated with increases in serum lactate and white blood cell count by day 5 of infusion, effects that were absent in the triple-combination group (GHRP-2 + TRH + GnRH)6. This metabolic signal warrants consideration in incomplete hormonal reactivation scenarios.

GHRP-2 infusion has also been reported to suppress pulsatile TSH secretion by approximately 50% in critically ill patients and to antagonize GHRH-stimulated TSH release7, a finding relevant when considering use in patients with already-compromised thyroid axis function.

Intranasal administration in children over 48 weeks was well tolerated with no specific adverse events reported20.

No drug interaction data, carcinogenicity data, or long-term safety data beyond 5-day infusion windows are available from the studies reviewed.

§06History

GHRP-2 belongs to a family of synthetic GH-releasing peptides first developed in the 1970s and 1980s through systematic structure-activity relationship studies of enkephalin analogs by Cyril Bowers and colleagues, who discovered that certain opioid-related pentapeptides unexpectedly stimulated GH release. This foundational work ultimately led to the identification of GHRP-6 and subsequently the more potent GHRP-2 (pralmorelin), which demonstrated superior GH-stimulating potency with reduced opioid-related side effects.

A pivotal insight came with the discovery of the GHS-R1a receptor in the late 1990s and the identification of ghrelin in 1999 as its endogenous ligand, retroactively establishing GHRP-2 as a synthetic ghrelin mimetic. This repositioned GHRP-2 within a broader physiological framework involving appetite, energy homeostasis, and GH regulation.

From the mid-1990s through the 2010s, a highly productive research program led by Greet Van den Berghe, Johan Veldhuis, and Bowers generated foundational evidence for GHRP-2's neuroendocrine actions in critical illness3,4,5,6,7,8 and healthy aging populations1,9,10,12,13. These studies established the synergistic GHRH+GHRP-2 paradigm4,5, the multi-axis reactivation potential in critical illness6, and the complex sex-steroid modulation of GHRP-2 efficacy1,9,12.

In Japan, pralmorelin (GHRP-2) received regulatory approval as a diagnostic agent for GH deficiency testing. Clinical development as a therapeutic growth promoter in GH-deficient children via intranasal delivery was evaluated but did not demonstrate significant growth efficacy20. Research into GHRP-2's role in neuroendocrine recovery, aging, and metabolic regulation continues across multiple academic centers.

§07References